Domantis signs deal with ImClone
11 March, 2003 by Graeme O'NeillUS anti-cancer therapeutics company ImClone Systems has signed an agreement with UK antibody engineering company Domantis, to use Domantis' proprietary domain-antibody technology to develop new therapeutics.
Remicade royalty refusal beggars analysis
04 March, 2003 by Graeme O'NeillUS biomedical company Centocor continues to puzzle analysts and investors alike with its refusal to pay royalties on its market-leading rheumatoid arthritis therapy Remicade to small Sydney biotechnology company Peptech.
CK Life, Swinburne team to trial ancient remedy as potential AIDS vaccine
03 March, 2003 by David BinningCK Life Sciences, the biotech child of Asian business tycoon Li Ka Shing, will this month start an Australian trial of an AIDS vaccine drawn from ancient Chinese herbal remedies after inking a $600,000 deal with the Swinburne University Graduate School of Integrative Medicine.
ErbB2 research may give key to cancer growth
28 February, 2003 by Melissa TrudingerResearchers at the CRC for Cellular Growth Factors have determined the structure of ErbB2, providing an important clue in how the molecule may contribute to the uncontrolled growth of cancer cells.
Bionomics, Florey in epilepsy collaboration
26 February, 2003 by Graeme O'NeillAdelaide biomed company Bionomics (ASX: BNO) has established a strategic research collaboration with the Howard Florey Institute of Experimental Physiology and Medicine that it hopes will speed its development of new drugs for epilepsy and other brain disorders.
HIV vaccine research landscape 'not all doom and gloom'
25 February, 2003 by Graeme O'NeillNew approaches mean there is still hope for an effective HIV vaccine, Australian researchers have said in the wake of today's release of disappointing AIDS vaccine results by US company VaxGen.
WEHI scientist wins Eppendorf research award
21 February, 2003 by Melissa TrudingerHamish Scott, of Melbourne's Walter and Eliza Hall Institute of Medical Research, was presented with the Eppendorf Award for Young Australian Researchers at this week's 24th Lorne Genome Conference.
Garvan celebrates 40 years
18 February, 2003 by Iain ScottSydney's Garvan Institute of Medical Research yesterday threw a party to celebrate its 40th birthday.
NHMRC guidelines recommend embryo access freeze
14 February, 2003 by Pete YoungA freeze on access by researchers to any human embryo not in storage for at least one year is among proposed official guidelines on the use of embryonic stem cells released this week by the National Health and Medical Research Council (NHMRC).
Takeover bid made for Sirtex
12 February, 2003 by Iain ScottUS company Cephalon has made a $AUD271 million takeover offer for Sydney-based cancer treatment company Sirtex Medical.
Allergan deal paying off for Peplin
11 February, 2003 by Pete YoungThe first fruits of anti-cancer drug developer Peplin Biotech's landmark licensing deal with US pharmaceutical company Allergan have surfaced in the form of a 240 per cent surge in Peplin's first-half revenues.
Malaria vaccine at least eight years away, conference told
10 February, 2003 by Graeme O'NeillVeteran Melbourne malaria researcher Prof Robin Anders believes a malaria vaccine is still at least eight to 15 years away -- but he is optimistic that a vaccine is feasible, and will be effective, despite the phenomenal capacity of the parasite, Plasmodium falciparum, to take evasive action against drugs and vaccines.
New cancer genomics centre opens at Peter Mac
04 February, 2003 by Melissa TrudingerThe new Ian Potter Foundation Centre for Cancer Genomics and Predictive Medicine was opened today at the Peter MacCallum Cancer Institute by Victorian Innovation Minister John Brumby.
VRI happy with H. pylori diagnostic study
03 February, 2003 by Melissa TrudingerVRI BioMedical's OncoAlert diagnostic test has performed well in a clinical study examining the test's ability to diagnose Helicobacter pylori infections.
Malaria parasite gene targets identified
31 January, 2003 by Graeme O'NeillA Melbourne-Philadelphia research team has provided a graphic demonstration of the power of genomics and bioinformatics by identifying a host of prospective drug targets in the malaria parasite, Plasmodium falciparum.
